Full Press Release Here.

Embarc Collective is expanding its bench of coaches with the addition of Dr. Tinashe Chandauka as our new Healthcare and Life Sciences Coach. Before joining Embarc Collective’s roster of expert coaches, Dr. Chandauka was an Entrepreneur-in-Residence at Texas Medical Center Innovation’s Accelerator for Cancer Therapeutics (ACT) and was selected as a Termeer Fellow, the most prestigious US network for first-time CEOs of early-stage biotech and life sciences organizations. With a robust background spanning medicine, venture-backed biotech, and early-stage company building, Dr. Chandauka brings deep expertise in translating scientific discovery into scalable therapeutics.

In addition to joining as a coach, his company, TMAB Therapeutics, is also joining Embarc Collective as a member. TMAB Therapeutics is developing next-generation therapies to treat solid tumors, with a focus on overcoming resistance mechanisms in cancers such as lung, ovarian, and colorectal. The company’s work in multi-specific antibodies and radiopharmaceuticals reflects the type of cutting-edge bio/pharma innovation continuing to take root in the region.

This milestone reflects a continued investment in bringing experienced operators and domain experts into the community—particularly those building at the intersection of science, healthcare, and venture-backed innovation. By welcoming both a seasoned founder and a cutting-edge biotech company, Embarc Collective is reinforcing its role as a platform where high-growth startups can access the relationships, insights, and infrastructure needed to scale.

This announcement underscores two broader strategic priorities. First, Expanding Founder Support Through Deep Domain Expertise: by onboarding leaders like Tinashe, Embarc Collective is deepening its bench of specialized coaches who can guide founders through the unique complexities of building in regulated, research-intensive industries like life sciences.

Second, building a stronger pipeline for healthtech and life sciences: the addition of TMAB Therapeutics reflects continued momentum in attracting and supporting high-potential healthcare startups, while deepening Embarc Collective’s active collaboration with leading regional institutions, including Moffitt Cancer Center and SPEROS FL, to advance innovation, commercialization, and company growth in the region.

Together, these efforts position Embarc Collective to play an even more central role in advancing Tampa Bay’s emergence as a hub for healthtech and life sciences innovation, connecting founders to both world-class expertise and a rapidly growing ecosystem.